{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:46:28Z","timestamp":1768250788660,"version":"3.49.0"},"reference-count":30,"publisher":"Center for Academic Publications Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Nutritional Science and Vitaminology, J Nutr Sci Vitaminol","J Nutr Sci Vitaminol","JNSV"],"published-print":{"date-parts":[[2017]]},"DOI":"10.3177\/jnsv.63.96","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T22:09:25Z","timestamp":1495750165000},"page":"96-103","source":"Crossref","is-referenced-by-count":16,"title":["The Impact of Supplementation with Folic Acid on Homocysteine Concentration and Selected Lipoprotein Parameters in Patients with Primary Hypertension"],"prefix":"10.3177","volume":"63","author":[{"given":"Aleksandra","family":"BASZCZUK","sequence":"first","affiliation":[{"name":"Department of Laboratory Diagnostics, University of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"THIELEMANN","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"MUSIALIK","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Metabolic Disorders and Hypertension, University of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"KOPCZYNSKI","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Metabolic Disorders and Hypertension, University of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"BIELAWSKA","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"DZUMAK","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zygmunt","family":"KOPCZYNSKI","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"WYSOCKA","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, University of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1759","reference":[{"key":"1","unstructured":"1) Baszczuk A, Musialik K, Kopczynski J, Thielemann A, Kopczynski Z, Kesy L, Dopierala G. 2014. Hyperhomocysteinemia, lipid and lipoprotein disturbances in patients with primary hypertension. Adv Med Sci 59: 68-73."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Antoniades C, Anatolonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. 2009. Homocysteine and coronary atherosclerosis: from folate fortification to recent clinical trials. Eur Heart J 30: 6-15.","DOI":"10.1093\/eurheartj\/ehn515"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Homocysteine Studies Collaboration. 2002. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015-2022.","DOI":"10.1001\/jama.288.16.2015"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Homocysteine Lowering Trialists’ Collaboration. 2005. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 82: 806-812.","DOI":"10.1093\/ajcn\/82.4.806"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Zhang M, Wen J, Wang X, Xiao C. 2014. Highdose folic acid improves endothelial function by increasing tetrahydrobiopterin and decreasing homocysteine levels. Mol Med Rep 10: 1609-1613.","DOI":"10.3892\/mmr.2014.2332"},{"key":"6","unstructured":"6) Shai I, Stampfer MJ, Ma J, Manson JE, Hankinson SE, Cannuscio C, Selhub J, Curhan G, Rimm EB. 2004. Homocysteine as a risk for coronary heart disease and its association with inflammatory biomarkers, lipids and dietary factors. Atherosclerosis 177: 375-381."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Tawakol A, Migrino RQ, Aziz KS, Waitkowska J, Holmvang G, Alpert NM, Muller JE, Fischman AJ, Gewirtz H. 2005. High-dose folic acid acutely improves coronary vasodilatator function in patients with coronary artery disease. J Am Coll Cardiol 45: 1580-1584.","DOI":"10.1016\/j.jacc.2005.02.038"},{"key":"8","unstructured":"8) Mierzecki A, Bukowska H, Honczarenko K, Jastrzebska M, Naruszewicz M. 2005. Wplyw malych dawek kwasu foliowego na wybrane biochemiczne czynniki ryzyka miazdzycy. Pol Merk Lek 19: 57-62."},{"key":"9","unstructured":"9) Sultan N, Khan MA, Malik S. 2007. Effect of folic acid supplementation on homocysteine level in postmenopausal women. J Ayub Med Coll Abbottabad 19: 78-81."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. 1999. The effect of folic acid fortification on plasma folate and total homocysteine concentration. N Engl J Med 19: 1449-1454.","DOI":"10.1056\/NEJM199905133401901"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Song Y, Cook NR, Albert CM, van Denburgh M, Manson JE. 2009. Effect of homocysteine-lowering treatment with folic acid and B vitamins of type 2 diabetes in women: a randomized controlled trial. Diabetes 58: 1921-1928.","DOI":"10.2337\/db09-0087"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Daly C, Fitzgerald AP, O’Callaghan, Collins P, Cooney MT, Graham IM; COMAC Group. 2009. Homocysteine increased the risk associate with hyperlipidaemia. Eur J Cardiovasc Prev Rehabil 16: 150-155.","DOI":"10.1097\/HJR.0b013e32831e1185"},{"key":"13","unstructured":"13) Liao D, Tan H, Hui R, Li Z, Jiang X, Gaubatz J, Yang F, Durante W, Chan L, Schafer AI, Pownall HJ, Yang X, Wang H. 2006. Hyperhomocysteinemia decreases high-density lipoprotein by inhibiting apolipoprotein A-I, protein synthesis and enhancing HDL cholesterol clearance. Circ Res 99: 598-606."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Obeid R, Herrmann W. 2009. Homocysteine and lipids: S-adenosyl methionine as a key intermediate. FEBS Lett 583: 1215-1225.","DOI":"10.1016\/j.febslet.2009.03.038"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Olszewski AJ, McCully KS. 1991. Homocysteine content of lipoproteins in hypercholesterolemia. Atherosclerosis 88: 61-68.","DOI":"10.1016\/0021-9150(91)90257-4"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Knekt P, Reunanen A, Alfthan G, Heliövaara M, Rissanen H, Marniemi J, Aromaa A. 2001. Hyperhomocysteinemia. A risk factor or a consequence of coronary heart disease? Arch Intern Med 161: 1589-1594.","DOI":"10.1001\/archinte.161.13.1589"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Papandreou D, Malindretos P, Arvanitidou M, Makedou A, Rousso I. 2010. Homocysteine lowering with folic acid supplements in children: effects on blood pressure. Int J Food Sci Nutr 61: 11-17.","DOI":"10.3109\/09637480903286371"},{"key":"18","unstructured":"18) Bukowska H, Goracy I, Zyzniewska-Banaszak E, Chelstowski K, Naruszewicz M. 2004. Ocena wplywu napoju zawierajacego sok owocowy, bakterie jogurtowe oraz witamine C i kwas foliowy na poziom homocysteiny, profil lipidowy i jakosc zycia oceniana rotterdamska lista symptomów, u mlodych mezczyzn. Czyn Ryz 1-2: 52-56."},{"key":"19","unstructured":"19) Guéant-Rodriguez RM, Spada R, Moreno-Garcia M, Anello G, Bosco P, Lagrost L, Romano A, Elia M, Guéant JL. 2011. Homocysteine is a determinant of ApoA-I and both are associated with ankle brachial index, in an ambulatory elderly population. Atherosclerosis 214: 480-485."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Mikael LG, Rozen R. 2008. Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB\/iNOS. Cardiovasc Res 80: 151-158.","DOI":"10.1093\/cvr\/cvn157"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, van Veldhuisen DJ. 2004. Folic Acid on Risk Diminishment After Acute Myocardial Infarction Study Group. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. Int J Cardiol 93: 175-179.","DOI":"10.1016\/j.ijcard.2003.02.001"},{"key":"22","unstructured":"22) Wald DS, Wald NJ, Morris JK, Law M. 2006. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 333: 1114-1117."},{"key":"23","unstructured":"23) Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr. 2006. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567-1577."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. NORVIT Trial Investigators. 2006. Homocysteine lowering and cardiovascular events after acute myocardial infraction. N Engl J Med 354: 1578-1588.","DOI":"10.1056\/NEJMoa055227"},{"key":"25","unstructured":"25) Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC. 2009. Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 72: 268-272."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Moens AL, Vrints CJ, Claeys MJ, Timmermans JP, Champion HC, Kass DA. 2008. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. Am J Physiol Heart Circ Physiol 294: H1971-1977.","DOI":"10.1152\/ajpheart.91503.2007"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Smulders YM, Blom HJ. 2011. The homocysteine controversy. J Inherit Metab Dis 34: 93-99.","DOI":"10.1007\/s10545-010-9151-1"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Joseph J. 2009. Quo vadis: Whither homocysteine research? Cardiovasc Toxicol 9: 53-63.","DOI":"10.1007\/s12012-009-9042-6"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) McCully KS. 2007. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 86: 1563S-1568S.","DOI":"10.1093\/ajcn\/86.5.1563S"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Cosentino F, Katusic ZS. 1995. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 91: 139-144.","DOI":"10.1161\/01.CIR.91.1.139"}],"container-title":["Journal of Nutritional Science and Vitaminology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnsv\/63\/2\/63_96\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T04:19:50Z","timestamp":1569385190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnsv\/63\/2\/63_96\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.3177\/jnsv.63.96","relation":{},"ISSN":["0301-4800","1881-7742"],"issn-type":[{"value":"0301-4800","type":"print"},{"value":"1881-7742","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}